A game changer in HER2 assessment for breast and gastric cancers – enabling accurate diagnosis and personalized treatments
Explore our decade-long journey and research collaboration with international experts. In this infographic, we highlight the potentially transformative impact of our AI-driven Precision Pathology solution on HER2-targeted treatment strategies for breast- and gastric cancer patients. This IVDR-cleared methodology is currently used in clinical practice for decision support when reading HER2-IHC assays. It enhances diagnostic accuracy, is optimized for concordance with HER2-FISH, significantly reduces the need for reflex testing, and has been shown to identify responders to anti-HER2 neoadjuvant chemotherapy.
We will soon release a whitepaper on this subject, which you can sign up to receive by submitting your email further down this page.
![](https://visiopharm.com/wp-content/uploads/HER2-infographic_FINAL_master-730x1005.png)
Whitepaper sign up
Share your email to get notified when the whitepaper is published.